Bristol-Myers Squibb Company (BMY) Earnings Call Transcripts
Bristol-Myers Squibb Company's Latest Earnings Call - Q2 FY2026
In Q2 2026, Bristol-Myers Squibb (BMY) reported total revenue of approximately $13 billion, reflecting a 5% year-over-year increase, driven primarily by a 14% rise in its growth portfolio. Adjusted diluted EPS was $2.04, and the company raised its full-year guidance for both revenue and adjusted EPS, citing strong performance and momentum in key products. The guidance revision includes an expected 20% to 25% growth in Eliquis revenue, offsetting a projected decline in the legacy portfolio.
Reported metrics
| Metric | Value |
|---|---|
| Total Revenue | $13B (beat) |
| Growth Portfolio Revenue | $7.6B (beat) |
| Adjusted EPS | $2.04 (beat) |
| Eliquis Revenue | $4.5B (beat) |
| Reblozyl Growth | 29% (positive) |
| Breyanzi Growth | 41% (positive) |
Guidance from management
Bristol-Myers Squibb raised its full-year 2026 revenue and adjusted EPS guidance, projecting Eliquis revenue growth of 20% to 25% and a legacy portfolio decline of 4% to 6%. Operating expenses are slightly increased to support prelaunch activities for CELMoDs and other growth initiatives.
What management said
And on guidance, Chris, look, it was -- you saw in the results, it was pretty pervasive across the growth portfolio. We saw really strong growth. Opdualag was up 22%; Reblozyl, 29%. Breyanzi, we continue to see great growth there, 41% and Camzyos was at 59%. And as we also talked about, the Qvantig now, we have 15% share. So well on our way to about 30% to 40%. It's now annualizing over $1 billion. So if you look at ...
And just to follow up, there would be no constraints with respect to the relationship that we have with Pfizer in terms of our ability to successfully launch and commercialize milvexian.
What analysts pressed on
Analysts expressed concerns over the delays in Milvexian and Cobenfy studies, questioning the impact on the company's growth trajectory. There were also inquiries about the sustainability of Eliquis revenue growth post-2026 and potential execution risks in ongoing studies.
Main topics on the call
- Revenue Growth Acceleration — Bristol-Myers Squibb's total revenue increased 5% year-over-year to approximately $13 billion, with the growth portfolio contributing $7.6 billion, up 14%. Management stated, "Our growth portfolio continued its strong pe...
- Guidance Increase — Management raised full-year 2026 revenue and adjusted EPS guidance due to strong first-half results. David Elkins noted, "Based on this first half momentum and confidence in our second half outlook, we are raising our fu...
- Pipeline Developments — Bristol-Myers Squibb is advancing a differentiated pipeline with multiple pivotal readouts expected by year-end. The company anticipates significant opportunities from drugs like Iberdomide and Mezigdomide, with PDUFA da...
- Eliquis Performance — Eliquis revenue grew by 21%, driven by strong demand and market share gains. David Elkins stated, "Eliquis delivered demand-driven growth of 21%, which nearly offset declines from generic entry across the remainder of th...
Read the full Bristol-Myers Squibb Company transcript (Q2 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Bristol-Myers Squibb Company
Bristol-Myers Squibb Company (BMY) is a publicly listed company in the Pharmaceuticals industry, within the Health Care sector. It trades on NYSE and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 119 calls on record spanning January 9, 2020 to July 30, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 119 Bristol-Myers Squibb Company earnings call transcripts on record, spanning January 9, 2020 to July 30, 2026. Based on this history, Bristol-Myers Squibb Company reports quarterly. The most recent call on file is dated July 30, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- BMY
- Exchange
- NYSE
- Country
- US
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Calls on record
- 119
- First call
- January 9, 2020
- Most recent
- July 30, 2026
- Reporting cadence
- quarterly